Annual report 2022/2023
DE
DE
Download Center

Why invest in BRAIN Biotech?

Five reasons to invest in BRAIN Biotech AG:

1. By investing in BRAIN Biotech AG, you are investing in sustainable growth in the dawning age of biology

Since the company was founded in 1993, BRAIN Biotech AG has developed from a sought-after specialist in biotechnological research and development into an integrated company that covers the entire value chain from laboratory through to production. With our disruptive bio-based products and solutions with a focus on nutrition, health, and the environment, we support the development of the economy towards a bioeconomy. We focus entirely on customers in the B2B segment.

2. With our solutions, we address some of the megatopics for a better, healthier, and more sustainable life

Our own R&D as well as the research programs we conduct together with our partners aim to develop solutions that lead to a better, healthier, and more sustainable life. Non-disclosure agreements prevent us from presenting all R&D programs publicly, but some highlights include:

  • Natural-based sweeteners: The identification and development of new natural-based sweeteners and sweetness enhancers.
  • Gold recycling from waste streams: Computer scrap, slag, and other waste of mineral origin: Biological extraction processes replace conventional chemical processes.
  • Battery recycling: Biological processes for recycling precious metals and lithium, together with our industrial partners.
  • Enzymatic cleansing of chronic wounds (Aurase): Painful and risky methods can be avoided; SolasCure spin-out in 2018 to implement the pharmaceutical approval process.
  • Nature-based substances: For tastier and healthier non-alcoholic drinks on a natural basis.
  • Circular economy in which waste is turned into raw materials: Carbon dioxide as a raw material for chemicals.
  • Identify plant-based antimicrobial candidates for food preservation: Can also be used for other industrial applications.
  • Active ingredient for the treatment of hereditary angioedema (rare hereditary disease): PHA121 in clinical development by our cooperation partner Pharvaris.
3. We actively contribute to more sustainable industrial production and entry into the circular economy

BRAIN Biotech is a leading company in the service of the bioeconomy. In this type of economy, biotechnological processes are harnessed for sustainable production on a natural basis. Our focus is on industrial biotechnology (“white biotechnology”).

Among other projects, we are striving to replace petrochemical processes with biotechnological processes on the basis of our proprietary collection of resources, the BRAIN BioArchive.

We improve industrial processes and develop new products and services by not limiting ourselves to individual analytical or molecular biological technologies. Our products and solutions directly address the following United Nations Sustainable Development Goals (UN SDGs): 2, 3, 6, 9, 12 and 13. More information and specific examples are presented in in our ESG and Sustainability Report: https://www.brain-biotech.com/content/files/financial_publications/2021-22/BRAIN_Biotech_Sustainability_Report_2022.pdf.

4. We have an attractive portfolio of biotechnology solutions and processes

We possess extensive and well-founded knowledge concerning enzymes, microorganisms, cell-based test systems, and bioactive natural compounds. An interdisciplinary approach enables us to conceive and develop completely new products and services for our customers.

We do not limit ourselves to individual technologies and methods, but instead leverage our broad technology portfolio.

Bioinformatics forms a central element of our R&D expertise for faster and better solutions. In addition to our employees’ experience, we rely here on state-of-the-art technologies in the machine learning and artificial intelligence areas.

The targeted modification and programming of cells is one of BRAIN Biotech’s core competencies. In this context, we deploy all commercially available technologies as well as our proprietary nucleases G-dase M® and G-dase E® for genome editing.

We are an expert solution provider for industry – from research and the scaling up of industrial biological processes to the production of enzymes and proteins.

More than thirty years of experience, around 600 available products for our B2B customers, and over 200 successfully completed industrial cooperation projects are strong testimony to our success.

5 We have embarked on a clear path towards profitable growth

We have been on a clear growth track again for the last two years. We aim to double the Group’s revenue in the medium term while at the same time increasing the adjusted EBITDA margin.

The BioProducts area is the Group’s primary growth segment. We have already invested heavily in expanding production capacity at our sites in recent years.

Our growth strategy is geographically focused on Europe and North America.

We offer highly innovative solutions and products for our customers through the close integration of our biotechnological research and production expertise.